For our suggestive pharmacogenetic findings, we used linear regression to determine if there was an equivalent pharmacogenetic association with change in systolic blood pressure and change in diastolic blood pressure (ΔSBP, ΔDBP respectively; that is, blood pressure at randomization minus blood pressure 6 months after randomization) for the stroke/NOS3 −690 C>T and all-cause mortality/NOS3 glu298asp G>T findings. This evidence concerns the gene NOS3 and stroke disorder.